Results 151 to 160 of about 11,606 (196)
Some of the next articles are maybe not open access.
Current Problems in Cancer, 1984
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +4 more sources
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +4 more sources
Current Oncology Reports, 2006
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Leukemia Research, 1987
A mother and son are reported who both developed hairy cell leukemia. The mother aged 74 presented with pancytopenia and responded well to splenectomy. Four years later her son aged 48 presented with pancytopenia; splenectomy was less effective but he improved after treatment with interferon-alpha. Histological examination of the splenic tissue in both
C G, Begley +5 more
openaire +2 more sources
A mother and son are reported who both developed hairy cell leukemia. The mother aged 74 presented with pancytopenia and responded well to splenectomy. Four years later her son aged 48 presented with pancytopenia; splenectomy was less effective but he improved after treatment with interferon-alpha. Histological examination of the splenic tissue in both
C G, Begley +5 more
openaire +2 more sources
Acta Haematologica, 2009
A 59-year-old man presented with lymphocytosis with huge splenomegaly. The abnormal lymphocytes had a high nucleoplasmxytoplasm ratio, a prominent nucleolus and hairy cytoplasmic projections. Immunophenotyping revealed B-cell leukemia with negative reactions to CD5 and CD25. Cytogenetic study showed 46, XY, der(5)t(5;6)(q35;p21), del(7)(p13)/ 46, idem,
P, Dunn, L Y, Shih, Y S, Ho, H F, Tien
openaire +2 more sources
A 59-year-old man presented with lymphocytosis with huge splenomegaly. The abnormal lymphocytes had a high nucleoplasmxytoplasm ratio, a prominent nucleolus and hairy cytoplasmic projections. Immunophenotyping revealed B-cell leukemia with negative reactions to CD5 and CD25. Cytogenetic study showed 46, XY, der(5)t(5;6)(q35;p21), del(7)(p13)/ 46, idem,
P, Dunn, L Y, Shih, Y S, Ho, H F, Tien
openaire +2 more sources
Cladribine in Hairy Cell Leukemia
Hematology/Oncology Clinics of North America, 2006Cladribine results in prolonged complete remissions in most patients wo have HCL. Several studies have indicated that patients who are in complete remission have survivals that are comparable to those of normal age-matched controls. HCL-related mortality is distinctly uncommon.
Rajesh, Belani, Alan, Saven
openaire +2 more sources
Hairy cell leukemia: an update
Current Opinion in Hematology, 2003Hairy cell leukemia is an indolent, chronic B-cell lymphoproliferative disorder comprising approximately 2 to 3% of all adult leukemias in the United States. Hairy cells are clonal expansions of mature, activated B-cells. They co-express CD11c, CD19, CD20, CD22, CD25, and CD103.
Grant R, Goodman +2 more
openaire +2 more sources
Clinical Lymphoma and Myeloma, 2009
Progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease. With current regimens, the majority of patients achieve a complete remission, and their survival curves are similar to those for appropriate age-matched individuals without the disease.
openaire +2 more sources
Progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease. With current regimens, the majority of patients achieve a complete remission, and their survival curves are similar to those for appropriate age-matched individuals without the disease.
openaire +2 more sources
Treatment of hairy cell leukemia
Expert Review of Hematology, 2020Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology.
Dai, Chihara, Robert J, Kreitman
openaire +2 more sources
Immunophenotype of hairy‐cell leukemia
European Journal of Haematology, 199015 cases of HCL were studied with a panel of monoclonal antibodies against different leukocyte antigens. A B‐cell phenotype different from that of B‐CLL was observed (CD10‐, CD19+, CD20+, CD21‐, CD22+, CD37+, CD38‐, FMC7+, LN1+, PCA‐1+, BLy7+and CD5‐).
I B, Hassan, H, Hagberg, C, Sundström
openaire +2 more sources
Macroglobulinemia and Hairy-Cell Leukemia
New England Journal of Medicine, 1977Leukemic reticuloendotheliosis, or hairy-cell leukemia, is a distinct clinical entity characterized by the proliferation of cells that have prominent cytoplasmic projections and contain the tartrate-resistant isozyme 5 of acid phosphatase.1 2 3 Although the clinical and morphologic features of this disease are widely known, there is considerable ...
D W, Golde, A, Saxon, R H, Stevens
openaire +2 more sources